The story that the market sees is all about Liptor, the wildly successful treatment for high cholesterol.  The patent for Liptor expires in 2011, and the market is concerned that Pfizer won’t be able to pick up the slack when generics close in on Liptor’s market when the patent expires.  A subtext to this...
Read More »